Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2022 5
2023 5
2024 5
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
Caballero-Ávila M, Martín-Aguilar L, Pascual-Goñi E, Michael MR, Koel-Simmelink MJA, Höftberger R, Wanschitz J, Alonso-Jiménez A, Armangué T, Baars AE, Carbayo Á, Castek B, Collet-Vidiella R, De Winter J, Del Real MÁ, Delmont E, Diamanti L, Doneddu PE, Hiew FL, Gallardo E, Gonzalez A, Grinzinger S, Horga A, Iglseder S, Jacobs BC, Jauregui A, Killestein J, Pozza EL, Martínez-Martínez L, Nobile-Orazio E, Ortiz N, Pérez-Pérez H, Poppert KN, Ripellino P, Roche JC, Rodriguez de Rivera FJ, Rostasy K, Sparasci D, Tejada-Illa C, Teunissen CCE, Vegezzi E, Xuclà-Ferrarons T, Zach F, Wieske L, Eftimov F, Lleixà C, Querol L. Caballero-Ávila M, et al. Among authors: baars ae. Ann Neurol. 2025 Mar;97(3):529-541. doi: 10.1002/ana.27142. Epub 2024 Nov 27. Ann Neurol. 2025. PMID: 39601182
Patient-Reported Outcome Measures for Assessing Health-Related Quality of Life in Patients With Polyneuropathies, Focusing on Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy: A Systematic Review of Measurement Properties.
Pelouto F, Baars AE, Papri N, Haagsma JA, Jacobs BC, Terwee CB. Pelouto F, et al. Among authors: baars ae. J Peripher Nerv Syst. 2025 Jun;30(2):e70022. doi: 10.1111/jns.70022. J Peripher Nerv Syst. 2025. PMID: 40366569 Free PMC article.
Evolution of SARS-CoV-2 antibody repertoire after successive mRNA vaccinations under immunosuppressive treatment.
Keijser JBD, Stalman EW, Wieske L, Steenhuis M, van Dam KPJ, Kummer LYL, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Blanco LF, Verstegen NJM, Keijzer S, van Mierlo G, Cristianawati O, Boogaard AJ, van der Straten K, van Rijswijk J, van Gils MJ, Ten Brinke A, van Ham SM, Kuijpers TW, Eftimov F, Rispens T; T2B! Immunity against SARS-CoV-2 study group. Keijser JBD, et al. EBioMedicine. 2025 Mar;113:105620. doi: 10.1016/j.ebiom.2025.105620. Epub 2025 Feb 25. EBioMedicine. 2025. PMID: 40010153 Free PMC article.
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseases.
Wieske L, Stalman EW, van Dam PJK, Kummer LY, Steenhuis M, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink G, Van der Kooi A, Raaphorst J, Löwenberg M, Takkenberg B, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl A, Broens B, Parra Sanchez A, van Els CACM, Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, Van der Pol WL, Goedee HS, Keijzer S, Keijser J, Cristianawati O, Ten Brinke A, Verstegen NJM, Zwinderman KAH, van Ham SM, Kuijpers TW, Rispens T, Eftimov F; T2B! immunity against SARS-CoV-2 study group. Wieske L, et al. Among authors: baars ae. Ann Rheum Dis. 2023 Jun;82(6):883-885. doi: 10.1136/ard-2022-223464. Epub 2023 Jan 31. Ann Rheum Dis. 2023. PMID: 36720583 No abstract available.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
van Dam KPJ, Wieske L, Stalman EW, Kummer LYL, Roosen J, van Kempen ZLE, Killestein J, Volkers AG, Boekel L, Wolbink GJ, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Sanchez AP, van Els CACM, de Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart RCF, Teng YKO, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Keijser JBD, Cristianawati O, Rispens T, Brinke AT, Verstegen NJM, Marieke van Ham S, Tas SW, Kuijpers TW, Eftimov F; T2B! Immunity against SARS-CoV-2 study group. van Dam KPJ, et al. Among authors: baars ae. J Autoimmun. 2023 Feb;135:102984. doi: 10.1016/j.jaut.2022.102984. Epub 2023 Jan 2. J Autoimmun. 2023. PMID: 36621174 Free PMC article.
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Stalman EW, Wieske L, van Dam KPJ, Kummer LY, van Kempen ZLE, Killestein J, Volkers AG, Tas SW, Boekel L, Wolbink GJ, Van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, D'Haens GRAM, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Voskuyl AE, Broens B, Parra Sanchez A, van Els CACM, Wit J, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng OYK, van Paassen P, Busch MH, Jallah PBP, Brusse E, van Doorn PA, Baars AE, Hijnen DJ, Schreurs CRG, Van der Pol WL, Goedee HS, Steenhuis M, Keijzer S, Keijser JBD, Boogaard A, Cristianawati O, Ten Brinke A, Verstegen NJM, Zwinderman KAH, Rispens T, van Ham SM, Kuijpers TW, Eftimov F; T2B! immunity against SARS-CoV-2 study group. Stalman EW, et al. Among authors: baars ae. Ann Rheum Dis. 2022 Dec;81(12):1757-1766. doi: 10.1136/ard-2022-222904. Epub 2022 Sep 5. Ann Rheum Dis. 2022. PMID: 36357161
Patient-reported daily functioning after SARS-CoV-2 vaccinations in autoimmune neuromuscular diseases.
van Dam KPJ, Wieske L, Stalman EW, Kummer LYL, van der Kooi AJ, Raaphorst J, van de Beek D, Verschuuren JJGM, Ruiter AM, Brusse E, van Doorn PA, Baars AE, van der Pol WL, Goedee HS, Ten Brinke A, van Ham SM, Rispens T, Kuijpers TW, Eftimov F; T2B! Immunity Against SARS‐CoV‐2 Study Group. van Dam KPJ, et al. Among authors: baars ae. Eur J Neurol. 2024 Dec;31(12):e16409. doi: 10.1111/ene.16409. Epub 2024 Sep 5. Eur J Neurol. 2024. PMID: 39236312 Free PMC article.
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases.
Wieske L, Kummer LYL, van Dam KPJ, Stalman EW, van der Kooi AJ, Raaphorst J, Löwenberg M, Takkenberg RB, Volkers AG, D'Haens GRAM, Tas SW, Spuls PI, Bekkenk MW, Musters AH, Post NF, Bosma AL, Hilhorst ML, Vegting Y, Bemelman FJ, Killestein J, van Kempen ZLE, Voskuyl AE, Broens B, Sanchez AP, Wolbink G, Boekel L, Rutgers A, de Leeuw K, Horváth B, Verschuuren JJGM, Ruiter AM, van Ouwerkerk L, van der Woude D, Allaart CF, Teng YKO, van Paassen P, Busch MH, Jallah BP, Brusse E, van Doorn PA, Baars AE, Hijnen D, Schreurs CRG, van der Pol WL, Goedee HS, Steenhuis M, Rispens T, Ten Brinke A, Verstegen NJM, Zwinderman KAH, van Ham SM, Kuijpers TW, Eftimov F; T2B! immunity against SARS-CoV-2 study group. Wieske L, et al. Among authors: baars ae. BMC Med. 2022 Mar 2;20(1):100. doi: 10.1186/s12916-022-02310-7. BMC Med. 2022. PMID: 35236350 Free PMC article.
18 results